BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38245834)

  • 1. Clinical significance of decreased or loss of ABO blood group expression in acute myeloid leukaemia: A single-centre retrospective study.
    Han JH; Lee H; Kim JK; Yoo J; Park K; Jekarl DW; Kim Y
    Vox Sang; 2024 Apr; 119(4):353-362. PubMed ID: 38245834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical and prognostic significance of ABO promotor methylation level in adult leukemia and myelodydysplastic syndrome].
    Shao M; Tang P; Lyu XP; Yang QK; Zhu WT; Jin HF; Wang L; Zhao XQ; Liu X; Sun L
    Zhonghua Nei Ke Za Zhi; 2018 Nov; 57(11):816-823. PubMed ID: 30392237
    [No Abstract]   [Full Text] [Related]  

  • 3. [Comparison of Weak ABO Antigen and Normal ABO Antigen in Patients with Acute Leukemia].
    Shao M; Lyu XP; Tang P; Yang QK; Zhu WT; Song J; Kong YK; Wang J; Sun L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1307-1313. PubMed ID: 29070100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between diminished miRNA expression and the disease status of AML patients: Comparing to healthy control.
    Chen DP; Chang SW; Wen YH; Wang WT
    Biomed J; 2023 Apr; 46(2):100518. PubMed ID: 35307582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential association of the transcription levels of the ABO gene with the disease phases in AML patients.
    Zhang W; Liu J; Zhang W; Zhuang Y
    Transfus Apher Sci; 2017 Oct; 56(5):719-722. PubMed ID: 28939368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABO Blood Type Incompatibility Is Not a Risk Factor of Outcomes for Acute Myeloid Leukemia (AML) Patients After Unmanipulated Haplo-identical Peripheral Blood Hematopoietic Stem Cell Transplantation.
    Yang N; Guan L; Liu Z; Ding Y; Zhu C; Luo L; Wang F; Fang S; Gao Z; Gu Z; Gao C
    Ann Transplant; 2019 Jun; 24():350-358. PubMed ID: 31197126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Correlation between DNA methylation of the ABO gene promoter CpG island and leukemia].
    Xu H; Bao GQ; Wang BY; Xing HX; Ye SH; Zhang JG; Yu CY; Tan YX; Zhang YP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Apr; 16(2):240-6. PubMed ID: 18426641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of ABO incompatibility on patients' outcome after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia - a report from the Acute Leukemia Working Party of the EBMT.
    Canaani J; Savani BN; Labopin M; Huang XJ; Ciceri F; Arcese W; Tischer J; Koc Y; Bruno B; Gülbas Z; Blaise D; Maertens J; Ehninger G; Mohty M; Nagler A
    Haematologica; 2017 Jun; 102(6):1066-1074. PubMed ID: 28255020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of DNA methylation on ABO gene expression in leukemia].
    Shao M; Lyu XP; Yang QK; Zhu WT; Song J; Kong YK; Wang J; Sun L; Wang F
    Zhonghua Xue Ye Xue Za Zhi; 2016 Sep; 37(9):795-799. PubMed ID: 27719724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
    Pituch-Noworolska A
    Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic value of RASGEF1A RNA expression and DNA methylation in cytogenetically normal acute myeloid leukemia.
    He X; Zhang W; Fu W; Liu X; Yang P; Wang J; Zhu M; Li S; Zhang W; Zhang X; Dong G; Yan C; Zhao Y; Zeng Z; Jing H
    Cancer Biomark; 2023; 36(2):103-116. PubMed ID: 36404533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression analysis, clinical significance and potential function of PLXNB2 in acute myeloid leukaemia.
    Guo Z; Guo D; Kong D; Bian S; Zhao L; Li Q; Lin L; Hao J; Sun L; Li Y
    Mol Biol Rep; 2023 Oct; 50(10):8445-8457. PubMed ID: 37632633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic methylation markers for overall survival in cytogenetically normal patients with acute myeloid leukemia treated on SWOG trials.
    Qu X; Othus M; Davison J; Wu Y; Yan L; Meshinchi S; Ostronoff F; Estey EH; Radich JP; Erba HP; Appelbaum FR; Fang M
    Cancer; 2017 Jul; 123(13):2472-2481. PubMed ID: 28222251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT.
    Canaani J; Savani BN; Labopin M; Michallet M; Craddock C; Socié G; Volin L; Maertens JA; Crawley C; Blaise D; Ljungman PT; Cornelissen J; Russell N; Baron F; Gorin N; Esteve J; Ciceri F; Schmid C; Giebel S; Mohty M; Nagler A
    Am J Hematol; 2017 Aug; 92(8):789-796. PubMed ID: 28439910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABO blood group incompatibility as an adverse risk factor for outcomes in patients with myelodysplastic syndromes and acute myeloid leukemia undergoing HLA-matched peripheral blood hematopoietic cell transplantation after reduced-intensity conditioning.
    Hefazi M; Litzow M; Hogan W; Gastineau D; Jacob E; Damlaj M; Hashmi S; Al-Kali A; Patnaik MM
    Transfusion; 2016 Feb; 56(2):518-27. PubMed ID: 26446051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical features and prognosis of core binding factor acute myeloid leukemia children in South China: a multicenter study].
    Guo BY; Wang Y; Li J; Li CF; Feng XQ; Zheng MC; Liu SX; Yang LH; Jiang H; Xu HG; He XL; Wen H
    Zhonghua Er Ke Za Zhi; 2023 Oct; 61(10):881-888. PubMed ID: 37803854
    [No Abstract]   [Full Text] [Related]  

  • 17. ABO identical and washed blood transfusions as candidate strategies to reduce early mortality in acute promyelocytic leukemia.
    Sahai T; Henrichs K; Refaai M; Heal JM; Kirkley SA; Schmidt AE; Mendler JH; Masel D; Liesveld J; Aquina C; Blumberg N
    Leuk Res; 2017 Nov; 62():1-3. PubMed ID: 28963906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive DNA repair gene expression analysis and its prognostic significance in acute myeloid leukemia.
    Park S; Kim YJ; Huh HJ; Chung HS; Lee M; Park YM; Mun YC; Seong CM; Huh J
    Hematology; 2021 Dec; 26(1):904-913. PubMed ID: 34789078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical Significance of Low Expression of LncRNA CASC15 in Acute Myeloid Leukemia with NPM1 Mutations].
    Xia PH; Xu ZJ; Jin Y; Ma JC; Wen XM; Yuan Q; Leng JY; Qian J; Lin J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Jun; 30(3):659-670. PubMed ID: 35680788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R/R-AML).
    Lu Y; Liu Y; Wen S; Kuang N; Zhang X; Li J; Wang F
    J Transl Med; 2022 Dec; 20(1):600. PubMed ID: 36517851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.